Anti-infective is
a common term used to illustrate any medicine which inhibits the spread of an
infectious organism or by killing of an infectious micro-organism inside the
body. Anti-infective encompasses of the antibiotics, anthelmintic, antifungal, anti-malarial,
anti-tuberculosis agents, anti-protozoals, and the antivirals. The working of
anti-infective includes interfering in biomolecular functioning of microbes such
as cell wall formation, replication, protein synthesis and many more.
According to
study, “Anti-Infective Drugs Global
Market Report 2019”
the key companies operating in the anti-infective drugs global market are Gilead,
GlaxosmithKline Plc., Wockhardt ltd, Boehringer Ingelheim, Roche, Allergen
Plc., Abbott Laboratories,
Inc., AstraZeneca Plc., Otsuka Pharmaceutical Co. Ltd., Gilead Sciences Inc., Merck
& Co. Inc., F. Hoffman-La Roche Ltd., Astellas Pharma Inc., Novartis AG, Pfizer
Inc., Sanofi, Johnson & Johnson Services Inc., Bayer AG, Bristol-Myers
Squibb Company. The companies have launched a panel of Food and Drug
Administration (FDA) approved adapted antibiotics for the treating of a soft
tissue infections and acute bacterial skin; these drugs include Sivextro
(Tedizolid), Orbactiv (Oritavancin), Dalvance (Dalbavancin), and Zevtera
(Ceftobiprole).
Based on the type
of drug, anti-infective drugs market is segmented into amebicides, anti-fungal
drugs, anthelmintics, anti-bacterial drugs, antimalarial agents, and anti-viral
drugs. The anti-fungal drugs include echinocandins (micafungin, caspofungin and
anidulafungin), azoles and polyenes. Among them azoles are expected to lead the
market owing to high ability of combat systemic fungal infections. Some of the
key anti-bacterial drugs are macrolides, B-lactams, tetracycline, quinolones,
aminoglycoside and others. Based on route of administration, market is segmented
into oral, topical, Intravenous (IV) and others. The oral route of
administration holds the largest market share due to strong pipeline and new
product development. Based on indication, market is segmented into sepsis,
pneumonia, tuberculosis, Methicillin-resistant Staphylococcus Aureus (MRSA),
dermatophytosis,
candidiasis, aspergillosis, HIV infection, hepatitis virus infection and respiratory
virus infection. Based on range, market is segmented into narrow spectrum and
broad spectrum. Moreover, based on distribution channel, market is segmented
into specialty pharmacy, retail pharmacy, hospital pharmacy and online sales.
The anti-infective
drugs global market is driven by high purchasing power for the expensive drugs,
and increase in prevalence of target diseases such as STIs, followed by presence
of favorable reimbursement policies. The hospital acquired infections,
respiratory viruses, growing geriatric population base and increase in
collaborative development efforts are some of the other key factors expected to
drive the market over the forecast period. Additionally, organizations, such as
the Centers for Disease control & Prevention (CDC) and World Health
Organization (WHO) are actively involved in spreading consciousness amongst people
for the serious implications of infectious diseases and importance of the early
treatment. Apart from key drivers, few of factors restraining the market growth
include high R&D cost, and development of multi-drug resistant organisms.
The North American
region holds the largest market share of anti-infective drugs market owing to
awareness among end-users such as clinicians & healthcare professionals followed
by the presence of sophisticated healthcare infrastructure in the region. In
addition, Asia-Pacific region is expected to witness considerable increase in CAGR
over the forecast period due to rise in economic stability, presence of
generics companies coupled with increase in disposable income and augmented
susceptibility supporting the market growth in the region.
For more
information, refer to below link:-
Related
Report:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
No comments:
Post a Comment